Agenda
Applications for consideration at this meeting
- 1522 PD-L1 (Programmed Death-Ligand 1) immunohistochemistry testing for access to pembrolizumab as first-line therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma (co-dependent)
- 1585 Genetic testing for the diagnosis of early-onset or familial neuromuscular disorders
- 1600 Genetic testing for heritable kidney disease (other than Alport syndrome)
- 1608 Amnion membrane (human tissue) for topical treatment of ophthalmic disorders (caused by disease and/or trauma), and wound dressings for skin burns and ulcers on the craniofacial area, torso, and limbs
- 1613 Permanent acute coronary syndrome event detector (insertion, removal or replacement of) for monitoring of the heart's electrical activity
- 1614 Magnetic resonance-guided focused ultrasound for the treatment of medically refractory essential tremor
- 1615 Transcatheter occlusion of the left atrial appendage for patients with non-valvular atrial fibrillation
- 1617 BRAF V600 testing to help determine eligibility for PBS access to Braftovi (encorafenib), in patients with metastatic colorectal cancer (Stage IV)
- 1618 Testing of tumour prostate tissue to detect BRCA1/2 pathogenic gene variants in men with metastatic castration-resistant prostate cancer to help determine eligibility for PBS olaparib
- 1619 Testing of blood to detect pathogenic germline BRCA1 or BRCA2 gene variants, in patients with metastatic pancreatic cancer to help determine eligibility for PBS olaparib
- 1620 Magnetic Resonance Image Guided Radiation Therapy
Related information
Committee: